What Europe's EU Inc. framework for boosting competitiveness can and should learn from startup fraud in the US

The European Union is currently considering EU Inc., a proposed framework designed to create a unified set of rules for starting, operating, and growing businesses across all EU member states. This framework aims to expedite business registration and operation within the EU, with potential company registration completed within 48 hours for less than €100 through fully digitized procedures.

It also includes digitized capital-raising and stock market access procedures, and simplified liquidation processes to make business dissolution and relaunch more seamless. This initiative is part of the EU's broader Startup and Scaleup Strategy, which seeks to reduce the innovation gap between the EU and its global competitors, particularly the United States.

The EU's venture capital market is reportedly smaller, and it has fewer unicorns and lower valuations for comparable companies compared to the U.S. However, in its pursuit to catch up with its North American counterpart, the EU must be cautious not to replicate some of the startup fraud practices prevalent in the U.S. A notable example of startup fraud is the case of Elizabeth Holmes and her biotech startup Theranos.

Holmes, a former founder, is currently serving a 135-month prison sentence for defrauding investors through elaborate schemes of fake product demos, falsified records, and staged research in her company's labs. The article emphasizes that while Holmes and Theranos represent one of many startup fraud cases, the issue runs deeper than commonly acknowledged.

The article suggests that the startup ecosystem, characterized by a culture of "creative destruction," highly liquid private capital markets, limited formal oversight, and technological hype cycles, creates conditions conducive to fraud. These conditions are evident in high-growth startup environments like Silicon Valley, where immense pressure to achieve rapid growth and secure unicorn status can encourage founders to blur the line between reality and fiction.

The study of startup fraud in Silicon Valley reveals that while many entrepreneurs start real businesses with genuine intentions, they often justify fraud to maintain investor and stakeholder commitment when expected technological, contract, or regulatory outcomes fall short.

Startup fraud can take various forms, ranging from reporting revenue from terminated contracts to creating falsified bank statements. Sophisticated forms of fraud involve creating a facade – a deceptive image of an exponentially growing company – to conceal performance issues. In the Theranos case, Holmes and her co-founder used fake product demonstrations, staged research, and impersonated high-profile customers and investors to mislead investors.

Additional forms of deception include fabricating official audit reports and falsely affirming regulatory compliance. Furthermore, due diligence processes designed to scrutinize startups can be manipulated by entrepreneurs, highlighting the severity of the problem. Investors often demand rapid growth, prompting entrepreneurs to employ ever more creative methods to meet those expectations, even if it means committing criminal offenses.